Dean Tsarwhas

A Phase II Single-arm Study of Palbociclib in Patients With HER2-positive Breast Cancer With Brain Metastases and Analysis of ctDNA in Patients With Active Brain Metastases.

Jenny C. Chang, M. Cristofanilli, B. Jovanovic, 2022, Clinical breast cancer.

Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2−negative endocrine-refractory metastatic breast cancer

A. Rademaker, W. Gradishar, M. Cristofanilli, 2020, Journal for ImmunoTherapy of Cancer.

Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial.

C. Nabhan, S. Newman, J. Bitran, 2009, Urology.

Medical Oncology Erlotinib Has Moderate Single-agent Activity in Chemotherapy-naïve Castration-resistant Prostate Cancer: Final Results of a Phase II Trial

C. Nabhan, S. Newman, J. Bitran, 2009 .

A phase II study of pembrolizumab and capecitabine for triple-negative (TN) and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer (MBC).

A. Rademaker, W. Gradishar, M. Cristofanilli, 2019, Journal of Clinical Oncology.